Table 1 Key clinical data in the model

Survival data

OS (HR), PD-L1 CPS > = 5

0.71 (95% CI:0.59–0.86)

-

[10]

-

PFS (HR), PD-L1 CPS > = 5

0.68 (95% CI: 0.56–0.81)

-

[10]

-

Median OS (months), PD-L1 CPS > = 5

14.4 (95% CI: 13.1–16.2)

11.1 (95% CI: 10.0-12.1)

[10]

-

Median PFS (months), PD-L1 CPS > = 5

7.7 (95% CI: 7.0-9.2)

6.0 (95% CI: 5.6–6.9)

[10]

-

OS (HR), All randomized

0.80 (95% CI:0.68–0.94)

-

[10]

-

PFS (HR), All randomized

0.77 (95% CI: 0.68–0.87)

-

[10]

-

Median OS (months), All randomized

13.8 (95% CI: 12.6–14.6)

11.6 (95% CI: 10.9–12.5)

[10]

-

Median PFS (months), All randomized

7.7 (95% CI: 7.1–8.5)

6.9 (95% CI: 6.6–7.1)

[10]

-

Grade 3 or 4 AEs, n (%)

Nausea

20 (3%)

19 (2%)

[10]

Beta

Diarrhea

35 (4%)

24 (3%)

[10]

Beta

Peripheral neuropathy

31 (4%)

22 (3%)

[10]

Beta

Vomiting

17 (2%)

24 (3%)

[10]

Beta

Fatigue

30 (4%)

16 (2%)

[10]

Beta

Anemia

47 (6%)

21 (3%)

[10]

Beta

Decreased appetite

14 (2%)

13 (2%)

[10]

Beta

Thrombocytopenia

19 (2%)

13 (2%)

[10]

Beta

Platelet count decreased

20 (3%)

19 (2%)

[10]

Beta

Peripheral sensory neuropathy

16 (2%)

14 (2%)

[10]

Beta

Aspartate aminotransferase increased

12 (2%)

5 (1%)

[10]

Beta

White blood cell count decreased

23 (3%)

13 (2%)

[10]

Beta

Alanine aminotransferase increased

6 (1%)

5 (1%)

[10]

Beta

Palmar-plantar erythrodysesthesia syndrome

11 (1%)

6 (1%)

[10]

Beta

Neutrophil count decreased

83 (11%)

67 (8%)

[10]

Beta

Neutropenia

118 (15%)

93 (12%)

[10]

Beta

Asthenia

7 (1%)

10 (1%)

[10]

Beta

Lipase increased

45 (6%)

16 (2%)

[10]

Beta

Utility (Range)

PFS

0.797 (0.638–0.956)

0.797 (0.638–0.956)

[14]

Beta

PD

0.577 (0.462–0.692)

0.577 (0.462–0.692)

[14]

Beta

Death

0

0

[14]

Beta